Lineage-negative markers (Lin-)

Lineage-negative (Lin-) markers refer to a collective set of cell surface antigens that are expressed on mature, differentiated hematopoietic cells but are absent on undifferentiated stem and progenitor cells [1]. This phenotypic classification is primarily used in laboratory and clinical settings to isolate hematopoietic stem cells (HSCs) and early progenitor populations from sources like bone marrow, peripheral blood, or umbilical cord blood [2]. A standard lineage cocktail typically includes antibodies against markers such as CD3, CD14, CD16, CD19, CD20, and CD56, which identify T cells, B cells, myeloid cells, and NK cells [1, 2]. By removing these lineage-positive cells through immunomagnetic or flow cytometric depletion, researchers can enrich for a Lin- population that exhibits high multi-lineage differentiation potential and self-renewal capabilities [3]. While not a single therapeutic target, the Lin- status is a critical biomarker for identifying cancer stem cells in hematologic malignancies and for preparing cell-based therapies in regenerative medicine [3, 4].

Other names

Lin-Lineage-depleted markersLineage-negative cell markersLin-negative

Not applicable; lineage-negative markers represent a phenotypic classification used for the identification and isolation of undifferentiated cells rather than a specific therapeutic drug target.